Visual agnosia

Summary

Visual agnosia (MONDO:0000685) is a disease (an umbrella term covering 7 Mondo subtypes). A subtype of mental disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	visual agnosia
Mondo ID	MONDO:0000685
DOID	DOID:0060155
NCIT	C35276
SNOMED CT	25762009
UMLS	C0234502
MedGen	115959
GARD	0027560
Is cancer (heuristic)	no

Also known as: visual agnosia · visual agnosia (disease) · visuoperceptual agnosia

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of mental disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › visual agnosia

Related subtypes (13): akinetopsia, cortical deafness, pain agnosia, tactile agnosia, psychosexual disorder, drug-induced mental disorder, alcohol-induced mental disorder, adjustment disorder, mood disorder, psychotic disorder, developmental disorder of mental health, anxiety disorder, disruptive behavior disorder

Subtypes (7): apperceptive agnosia, associative visual agnosia, color agnosia, form agnosia, topographical agnosia, alexia without agraphia, alexia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.